In the present nonrandomized pilot study we determined the role of the vaginally administered aromatase inhibitor anastrozole (0.25 mg anastrozole/d for 6 months) in the treatment of women with histologically proven r...In the present nonrandomized pilot study we determined the role of the vaginally administered aromatase inhibitor anastrozole (0.25 mg anastrozole/d for 6 months) in the treatment of women with histologically proven rectovaginal endometriosis. In a series of 10 patients, dysmenorrhea, physical and social functioning, but not chronic pelvic pain and dyspareunia, improved during therapy.展开更多
We performed two semen analyses in each of a small cohort of 11 GH- deficient (GHD) adolescents (mean age 18.1 ± 0.6 yrs), previously treated (mean 29 months prior) with either GH alone or GH and an aromatase inh...We performed two semen analyses in each of a small cohort of 11 GH- deficient (GHD) adolescents (mean age 18.1 ± 0.6 yrs), previously treated (mean 29 months prior) with either GH alone or GH and an aromatase inhibitor (anastrozole) for 12 months and compared their data with those of 10 healthy controls (mean age 18.7 ± 1.8 yrs). Although some adolescents had lower sperm parameters as compared to adult reference values, mean sperm concentrations, motility, and morphology were comparable among the 3 groups, suggestive that this small group of GHD adolescents previously treated with anastrozole has descriptively similar sperm parameters as other GHD and GH- sufficient adolescent controls.展开更多
Introduction.Endometrial stromal tumors with sex-cord-like elements are relatively rare.We rep ort a case of this neo-plasm with prolactin as a tumor marker for recurrent dis-ease.We also report response of recu rrent...Introduction.Endometrial stromal tumors with sex-cord-like elements are relatively rare.We rep ort a case of this neo-plasm with prolactin as a tumor marker for recurrent dis-ease.We also report response of recu rrent disease to pro-gesterone and aromatase inhibitor.Case report.A48-year-old woman was diagnosed with St age I endometrial stroma sarcoma with sex-cord compon ent at the time of hysterectomy for presumed fibroid u terus.One and a half years later,she presented with recu rrent disease in the abdomen associated with breast tend erness,galactorrhea,and an elevated prolactin level.She received three cycles of BEP(Bleomycin,Etoposide,Cisplatin)with partial response and followed by an optimal debulking procedure.Two out of a six additional planned cy cles of BEP wereadministered with complete tumor re sponse and normalized prolactin level.Second recurrence,9months later,again presented with galactorrhea and ris ing prolactin.Disease was progressive through three cycle s of Docetaxel and Gemcitabine therapy,but had an obje ctive response to treatment with anastrozole and megestrol acetate.Prolactin level normalized.Two years later th ere is stable disease and the patient remains symptom-fre e.Discussion.En-dometrial stromal sarcoma with sex-cord stromal component may be hormonally functional.Simil arly to pure endome-trial stromal sarcomas,they may respond to hormonal treatment,and further study is warranted.展开更多
The risk of tamoxifen related endome trial neoplasm has been confirmed by multiple studies.Especially rare en-dometrial tumors seem to develop more frequently under tamoxifen therapy.A recent analysis showed a substan...The risk of tamoxifen related endome trial neoplasm has been confirmed by multiple studies.Especially rare en-dometrial tumors seem to develop more frequently under tamoxifen therapy.A recent analysis showed a substantially higher risk for malignant mixed meso dermal tumor(MMMT;designated in the WHO classification of female genital tract neoplasms as carcinosarcoma )in association with tamoxifen intake.We are reporting a case of a 40-year -old multiparous premenopausa l woman who received tamoxifen 20mg daily for 2years afte r the surgical treat-ment of breast cancer and subsequent adjuvant chemother-apy.Two years after initiation of ta moxifen treatment,the patient developed anMMMTof the uterus.More than 64months after radical hysterectomy,salpingo -oophorecto-my,and pelvic lymphadenectomy,she remains recur-rence -free for MMMT.Unfortunately,she developed a local recurrence of her breast cancer in 2003.After surgi-cal treatment,she is currently bein g treated with anastro-zole.We are reporting a rare case of a premenopausal pa-tient who developed a MMMT within short time of tamoxifen exposure for stage I breast cancer.展开更多
文摘In the present nonrandomized pilot study we determined the role of the vaginally administered aromatase inhibitor anastrozole (0.25 mg anastrozole/d for 6 months) in the treatment of women with histologically proven rectovaginal endometriosis. In a series of 10 patients, dysmenorrhea, physical and social functioning, but not chronic pelvic pain and dyspareunia, improved during therapy.
文摘We performed two semen analyses in each of a small cohort of 11 GH- deficient (GHD) adolescents (mean age 18.1 ± 0.6 yrs), previously treated (mean 29 months prior) with either GH alone or GH and an aromatase inhibitor (anastrozole) for 12 months and compared their data with those of 10 healthy controls (mean age 18.7 ± 1.8 yrs). Although some adolescents had lower sperm parameters as compared to adult reference values, mean sperm concentrations, motility, and morphology were comparable among the 3 groups, suggestive that this small group of GHD adolescents previously treated with anastrozole has descriptively similar sperm parameters as other GHD and GH- sufficient adolescent controls.
文摘Introduction.Endometrial stromal tumors with sex-cord-like elements are relatively rare.We rep ort a case of this neo-plasm with prolactin as a tumor marker for recurrent dis-ease.We also report response of recu rrent disease to pro-gesterone and aromatase inhibitor.Case report.A48-year-old woman was diagnosed with St age I endometrial stroma sarcoma with sex-cord compon ent at the time of hysterectomy for presumed fibroid u terus.One and a half years later,she presented with recu rrent disease in the abdomen associated with breast tend erness,galactorrhea,and an elevated prolactin level.She received three cycles of BEP(Bleomycin,Etoposide,Cisplatin)with partial response and followed by an optimal debulking procedure.Two out of a six additional planned cy cles of BEP wereadministered with complete tumor re sponse and normalized prolactin level.Second recurrence,9months later,again presented with galactorrhea and ris ing prolactin.Disease was progressive through three cycle s of Docetaxel and Gemcitabine therapy,but had an obje ctive response to treatment with anastrozole and megestrol acetate.Prolactin level normalized.Two years later th ere is stable disease and the patient remains symptom-fre e.Discussion.En-dometrial stromal sarcoma with sex-cord stromal component may be hormonally functional.Simil arly to pure endome-trial stromal sarcomas,they may respond to hormonal treatment,and further study is warranted.
文摘The risk of tamoxifen related endome trial neoplasm has been confirmed by multiple studies.Especially rare en-dometrial tumors seem to develop more frequently under tamoxifen therapy.A recent analysis showed a substantially higher risk for malignant mixed meso dermal tumor(MMMT;designated in the WHO classification of female genital tract neoplasms as carcinosarcoma )in association with tamoxifen intake.We are reporting a case of a 40-year -old multiparous premenopausa l woman who received tamoxifen 20mg daily for 2years afte r the surgical treat-ment of breast cancer and subsequent adjuvant chemother-apy.Two years after initiation of ta moxifen treatment,the patient developed anMMMTof the uterus.More than 64months after radical hysterectomy,salpingo -oophorecto-my,and pelvic lymphadenectomy,she remains recur-rence -free for MMMT.Unfortunately,she developed a local recurrence of her breast cancer in 2003.After surgi-cal treatment,she is currently bein g treated with anastro-zole.We are reporting a rare case of a premenopausal pa-tient who developed a MMMT within short time of tamoxifen exposure for stage I breast cancer.
